Virtual Mentor

Virtual Mentor. April 2011, Volume 13, Number 4: 220-223.

Clinical Cases

  • Print
  • |
  • View PDF

Rationing Treatments Based on Their Cost per QALY

In deciding whether to ration treatments by their cost per QALY gained, we must consider how high to set that cost threshold and whether shorter-term benefits are also worth funding.

Commentary by David A. Wong, MD, MSc, FRCS(C)

Dr. Jackson is an orthopedic surgeon with an excellent record for good medical care and patient satisfaction. Over the last 5 years, her hospital’s financial security has declined and administrators have been looking at various options for reducing the cost of care. They have tentatively decided to phase out treatments and services that cost more than a certain amount per quality-adjusted life year (QALY). This will enable them, they feel, to provide the most health for their dollar, so to speak.

Dr. Jackson receives a letter from the hospital stating that she will no longer be able to offer treatments deemed insufficiently cost-effective. This includes the injection of epidural steroids for sciatica, a treatment that has resulted in crucial relief in the short term (about a month) for Dr. Jackson’s patients but, due to the need for repeat injections and the absolute expense of the treatment, has a high cost per QALY.

In disbelief, Dr. Jackson calls her friend Dr. Stein, one of the hospital administrators. She explains to Dr. Stein her view that patient care should not be affected by the cost of the services she uses, especially when the treatments have worked well for her patients; if treatments are clinically effective, they should be offered. Dr. Stein, himself a clinician, agrees personally with this view and knows of Dr. Jackson’s excellent record for patient satisfaction, but he says, “The hospital is going to go under: we simply can’t afford to spend the way we’ve been spending. You know as well as I do that if we close, many of our patients will have nowhere to go. We have to cut back somewhere; what do you suggest?”

Commentary

Ethical challenges are an inherent component of medical practice. Examples of these dilemmas have appeared in medical treatises as far back as Hippocrates’ exhortation to first do no harm. As we move into a new era of health care reform, ethical allocation of limited medical resources will become a more pressing challenge for the medical profession in the United States. Essentially, the quandary boils down to the conflict between society’s need to limit health care spending and medicine’s promise to provide effective care for individual patients.

American society’s discomfort with cost-effectiveness research and putting a price on human life and health (e.g., the debate over “death panels”) has kept the government from directly basing its coverage and payment decisions on this type of research. Instead, the 2009 Stimulus Bill HR-1 provided $1.1 billion for comparative effectiveness research (CER), comparing the effectiveness of two or more interventions, to the National Institutes of Health (NIH), the Center for Medicare and Medicaid Services (CMS), and the Agency for Healthcare Research and Quality (AHRQ) [1]. In addition, the United States Institute of Medicine (IOM) was charged with determining the top 100 priorities for CER [2].

Attention to basic health care economic analysis has been sadly lacking in medical curricula in the United States. Physicians must quickly educate themselves on both comparative effectiveness research and cost-effectiveness research. Otherwise, we will abdicate major medical treatment decisions to health economists, politicians, and government policymakers.

Rationing using the principle of cost effectiveness has been a cornerstone of health care delivery in many countries, most notably the United Kingdom (U.K.). Cost-effectiveness research generally compares the cost of a medical intervention or technology to a measure of the outcome’s value [3], often the quality-adjusted life year (QALY). The effectiveness of a procedure is thus generally reported as a dollar amount per quality-adjusted life year gained. The QALY measurement incorporates both the quality of health (as measured by a utility score) and the length of time (benchmark one year) over which the health state exists.

The ethical questions raised by rationing health services according to their cost effectiveness begin with setting the cost per QALY for which a medical treatment will be approved and reimbursed. The National Institute for Health and Clinical Excellence (NICE) in the U.K. has used a cost per QALY of £30,000 (approximately $48,000) as the threshold [4]. Thus, a treatment or technology costing less than this limit will generally be approved and an intervention costing more will be refused. By this criterion, even treatments with a definite positive clinical outcome will be unavailable from the National Health Service if their cost per QALY exceeds the threshold.

An example of a procedure that is limited in the U.K. and used frequently in the U.S. is the lumbar epidural steroid injection (ESI) for a herniated lumbar disc. Based on the findings of a randomized controlled trial by Price et al. [5], NICE eliminated epidural steroids as a reimbursed treatment for sciatica in the NHS because the authors calculated that the cost to improve a patient’s health status for a year (cost per QALY) was £354,171 (approximately $571,335). This figure far exceeds the £30,000 threshold that NICE uses to approve reimbursement.

Consider the ethical issues raised by this one example:

  • Should coverage decisions be made solely using class I [6] data, i.e., a single RCT, or should level II data such as large case series—which do not entail the expense and clinical difficulties of an RCT—be included in the decision-making process? I believe they should be, especially if outcomes for a particular treatment or technology can be reproduced and level-II conclusions become more reliable.
  • Ethically, what is a reasonable threshold to set the cost per QALY gained? There have been suggestions that $100,000 might be a figure that U.S. society would be willing to pay [7]. Of course, some people will consider it rationing to set any cost-per-QALY limit.
  • Should the benchmark for cost effectiveness be a year, or should we fund treatments with shorter periods of improvement? I do think there is a role for treatments such as ESI that result in shorter periods of improvement and thus are expensive when considered in isolation in a cost per QALY analysis. But if an ESI gives relief in the short term that, when combined with other treatments like medications and physiotherapy, can be part of a good outcome overall, one could argue that the combined-treatment approach (not just the ESI) should be considered in a cost analysis.
  • Is it ethical to withhold treatment based primarily on cost? My personal view is that cost is only one factor in clinical decision making and should not be made the sole determinant. Outcomes—prognosis for recovery of functional status—and other clinical factors—such as whether a condition is acute or chronic—should be major considerations in comparing treatments, not just cost effectiveness.

Clearly, the adoption of cost-effectiveness concerns into the United States health care system raises a number of ethical issues. To be active participants in formulating policy decisions which will impact day-to-day patient care, physicians must become familiar with the principles, methodology, and limitations of CER and cost comparisons and the associated ethical issues.



References

  1. Turkelson C. Comparative effectiveness: what’s it all about? AAOS Now. 2009;5(3). http://www.aaos.org/news/aaosnow/sep09/research4.asp. Accessed March 21, 2011.
  2. Institute of Medicine. Initial Priorities for Comparative Effectiveness Research. Washington, DC: National Academies Press; 2009.
  3. US Congressional Budget Office. Research on the Comparative Effectiveness of Medical Treatments: Issues and Options for an Expanded Federal Role; 2007. http://www.cbo.gov/ftpdocs/88xx/doc8891/12-18-ComparativeEffectiveness.pdf. Accessed March 21, 2011.
  4. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal; 2008. National Health Service. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed March 21, 2011.
  5. Price C, Arden N, Coglan L, Rogers P. Cost-effectiveness and safety of epidural steroids in the management of sciatica. Health Technol Assess. 2005;9(33):1-58, iii.
  6. Wright JG. A practical guide to assigning levels of evidence. J Bone Joint Surg Am. 2007;89(5):1128-1130.
  7. Kiewa K. What price health? Cost-effectiveness analysis can help society get the biggest bang for the buck. Harvard Public Health Review. 2004. http://www.hsph.harvard.edu/review/review_fall_04/risk_whatprice.html. Accessed March 21, 2011.

David A. Wong, MD, MSc, FRCS(C), is the director of the Advanced Center for Spinal Microsurgery at Presbyterian St. Luke’s Medical Center in Denver, Colorado. He is past president of the North American Spine Society (NASS) and co-chairs its Value Task Force and Performance Measures Advisory Committee.

How Comparative Effectiveness Research Feeds into Cost-Benefit Analyses, April 2011

The Role of Comparative Effectiveness Research in Developing Clinical Guidelines and Reimbursement Policies, January 2011

Quality of Life as the Basis of Health Care Resource Allocation: A Philosopher's Perspective on QALYs, February 2005

What's Wrong with Quality of Life as a Clinical Tool? February 2005

The people and events in this case are fictional. Resemblance to real events or to names of people, living or dead, is entirely coincidental. The viewpoints expressed on this site are those of the authors and do not necessarily reflect the views and policies of the AMA.